Thursday, November 21, 2024 11/21/2024

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

Award Number: DP2AT012346
ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

PROJECT SUMMARY This is a proposed supplement to Dr. Aaron Whiteley’s NIH Director’s New Innovator Award (DP2AT012346) titled “Deciphering the crosstalk between bacteria and their mammalian hosts”. Bacteria must defend themselves against the constant threat of bacteriophages (phages) and mobile genetic elements that seek to parasitize bacterial hosts for their selfish replication and spread. The conflict between bacteria and their threats has driven the evolution of genes that cooperate to form sophisticated signaling pathways to protect bacteria; these pathways collectively form the bacterial immune system. Interestingly, a subset of proteins found in the bacterial immune system are homologous to proteins in the human immune system, which provides a basis for cross-kingdom signaling, from bacteria to humans. The focus of this supplement is on understanding the bacterial immune system to improve our understanding and design of probiotic bacteria that might better survive in the human gut or influence human immune signaling pathways. The proposed goals for this supplement are to investigate the prevalence and function of known bacterial immune pathways in the microbiome and to uncover novel immune pathways that restrict horizontal gene transfer. In the first Aim, we will investigate the antiphage system CBASS (Cyclic Oligonucleotide Based Antiphage Signaling Systems) in the context of the human microbiome. CBASS is a potent antiphage system that is evolutionarily related to the human cGAS-STING antiviral pathway. A defining feature of CBASS systems is a CD-NTase (cGAS/DncV-like nucleotidyltransferase) protein, which is homologous to cGAS. Both cGAS and CD-NTases synthesize cyclic nucleotides that elicit potent immune signaling. In the parent grant, we investigate how cyclic nucleotides produced by bacteria in the gut may impact mammalian host immune signaling. This aim synergizes with that work by investigating the abundance of CBASS systems in metagenomes derived from healthy and disease-related mammalian microbiomes and interrogating their function in heterologous systems. In the second Aim, we will discover novel aspects of the bacterial immune system that restrict horizontal gene transfer by screening diverse bacteria using a functional assay. We will then assess the role of these systems in bacteria from the mammalian microbiome, including estimating their prevalence and disease association in metagenomes. The supplemental aims proposed will illuminate cryptic aspects of antiphage systems, interdomain signaling, and how bacteria control mobile genetic elements. Further, findings from this work will contribute to the ultimate development of novel pre- and probiotic complementary therapies that can durably remain within the human gut microbiome and even promote appropriate immune responses.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $91,505 )
2024	2024	THE REGENTS OF THE UNIVERSITY OF COLORADO	3100 MARINE ST	BOULDER	CO	80309	BOULDER	USA	Research and Training in Complementary and Integrative Health	000	1	9/3/2024	SUPPLEMENT FOR EXPANSION	$91,505
														Subtotal = $91,505

Issue Date FY: 2022 ( Subtotal = $1,385,900 )
2022	2022	REGENTS OF THE UNIVERSITY OF COLORADO, THE	3100 MARINE ST STE 481 572 UCB	BOULDER	CO	80309	BOULDER	USA	Trans-NIH Research Support	000	1	8/18/2022	NEW	$1,385,900
														Subtotal = $1,385,900

Grand Total All Awards = $1,477,405

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

Award Number: DP2AT012346

ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer